Vyepti®

Vyepti® (eptinezumab-jjmr) is a calcitonin-gene related peptide antagonist (CGRP) inhibitor that is used to prevent migraines in adults. Vyepti (pronounced VEE ep tee) was approved for use by the Food and Drug administration (FDA) in February 2020 and became available in April.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

Vyepti® Referral Form

MANUFACTURER:

Lundbeck Seattle Biopharmaceuticals

CLASS:
Biologics (CGRP ligand)
WHAT IT TREATS:
PRESCRIBED BY:

Neurologists

HOW ADMINISTERED:
IV Infusion
FREQUENCY:

Every three months

Length of infusion:
30 mins